Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NADPH Oxidase in Microvascular Dysfunction Post-GDM
NCT05946798Phase 1Active, not recruiting
- Start
- Aug 2023
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of apocynin and ng-nitro-l-arginine methyl ester in gestational diabetes mellitus (GDM) (4 arms). Primary endpoints: Microvascular acetylcholine-mediated dilation at 4 hours and Microvascular insulin-mediated dilation at 4 hours. Started Aug 2023; status: active, not recruiting.
02
Drugs
apocyninng-nitro-l-arginine methyl ester
03
Conditions
gestational diabetes mellitus (GDM)
Beyond the preview
Go deeper on NCT05946798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05946798.